Engflag

Amt

Quick links to important sections

Amt

Amt_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amt

Quick Facts

Property Description
Active Ingredients Amantadine, Beta-arteether
Pharmacological Class Antiviral, Antiparkinsonian, Antimalarial
Type Synthetic, Fixed-Dose Combination Product
Forms Tablet, Capsule, Solution for injection
Origin Adamantane and Artemisinin Derivatives

What Type of Medicine is Amt? (Identity and Classification)

Amt is defined as a synthetic, fixed-dose combination product containing two active ingredients from distinct pharmacological classes. This formulation's identity is characterized by the co-presence of an adamantane derivative and an artemisinin derivative. The primary components are Amantadine, which acts as both an antiviral and an antiparkinsonian agent, and Beta-arteether, which functions as a potent antimalarial agent. Amantadine is classified as an adamantane antiviral that targets the M2 protein of the Influenza A virus. Amantadine is used to manage certain viral infections and neurological symptoms. This combination represents a specific pharmacological strategy, recognized in clinical practice, to address multi-systemic issues within a single medication.

Composition and Available Forms of Amt (Structure and Delivery)

The core composition of Amt includes Amantadine (often as its salt form, Amantadine Sulfate) and Beta-arteether, formulated to allow for versatile administration. The drug is prepared in multiple high-level dosage forms, often including oral solid forms such as a tablet or capsule, and a specialized solution for injection. The availability of these forms supports different routes of administration, allowing for both oral intake and parenteral delivery. Artemisinin derivatives, such as Beta-arteether, are associated with efficacy against multi-drug resistant malaria parasites. This component is a key agent in the management of resistant parasitic diseases. A key differentiating factor is the inclusion of the salt form, Amantadine Sulfate, which is often favored in specific oral formulations for better stability and absorption characteristics.

What is the General Purpose of Amt? (High-Level Function)

The general purpose of Amt is to achieve multi-faceted therapeutic outcomes by addressing both neurological symptom management and the elimination of specific pathogens. This benefit arises from the independent actions of its ingredients: one ingredient helps to rebalance chemical signals in the brain and disrupt viral reproduction, while the other works to damage and eliminate disease-causing parasites. Typical use scenarios involve patients requiring simultaneous management of underlying neurological symptoms and clearance of specific parasitic infections. In essence, the medicine is designed to provide simultaneous support for managing complex neurological challenges and facilitating the clearance of certain infectious agents.

Regulatory References

  1. Amantadine - LiverTox - NIH

What side effects are possible with Amt?

Amt (Amiloride) is generally well tolerated, but like all medications, it can cause side effects. The most significant risk associated with Amiloride is hyperkalemia (elevated potassium levels in the blood), which can lead to serious and potentially fatal heart rhythm problems. Regular blood tests to monitor potassium levels are essential during treatment.

Common Side Effects

The most frequently reported side effects are generally mild and may decrease as the body adjusts to the medication. These can include gastrointestinal issues such as:

  • Nausea and Vomiting
  • Diarrhea or Constipation
  • Abdominal pain or upset stomach

Other common side effects reported are headache, dizziness or lightheadedness (especially when standing up quickly due to reduced blood pressure), and muscle cramps or weakness.

Serious Side Effects and Safety Warnings

Contact a healthcare provider immediately or seek emergency medical attention if any of the following signs or symptoms occur, as they could indicate a serious reaction or complication:

System/Condition Warning Signs
Cardiovascular Irregular or fast heartbeat, chest pain, difficulty breathing, shortness of breath.
Electrolyte Imbalance (Hyperkalemia) Confusion, numbness or tingling in the hands, feet, or lips, severe muscle weakness or heaviness in the legs.
Allergic Reaction Rash, itching, hives, swelling of the face, tongue, or throat.
Kidney Function Decrease in the amount of urine, swelling of the hands, ankles, or feet.

Amiloride is contraindicated in patients with a history of hyperkalemia, severe kidney impairment (such as anuria or diabetic nephropathy), or in those taking other potassium-sparing diuretics or potassium supplements, as these combinations significantly increase the risk of hyperkalemia. Use with caution in patients with diabetes, liver disease, or pre-existing heart conditions. Patients should not stop taking the medication abruptly without consulting their healthcare provider.

Overdose and Emergency Response

Amt Overdose and When to Seek Help

Alpha-methyltryptamine (Amt) overdose is a serious medical emergency that may result in life-threatening complications. As a substance that acts as a potent monoamine-releasing agent, especially for serotonin, high doses can lead to severe toxicity, including Serotonin Syndrome.

Overdose symptoms can manifest as significant cardiovascular effects and severe neurological changes. The duration of Amt's effects is long, and adverse reactions can persist for 12 to 24 hours, sometimes longer in cases of severe toxicity.

Warning Signs of Severe Toxicity or Overdose

System Symptoms
Cardiovascular Rapid, irregular heartbeat (Tachycardia), High Blood Pressure (Hypertension), Cardiac Arrhythmia
Neurological Confusion, Agitation, Seizures, Coma, Muscle rigidity, Hyperthermia (dangerously high body temperature)
Other Excessive sweating, Dilated pupils (Mydriasis), Vomiting

Immediate medical attention is necessary if any of these severe symptoms are present following Amt use. Do not attempt to manage a suspected overdose at home. The primary goal of medical treatment is supportive care and managing severe symptoms such as hyperthermia, seizures, and cardiovascular instability. Always contact emergency services or a poison control center immediately for guidance on managing a suspected overdose.

Therapeutic Uses of Amt

What Amt Treats: Main Uses and Benefits

Amt (Amitriptyline) is generally used to provide supportive symptom management across several clinical contexts where short-term symptomatic assistance is needed to help maintain a patient's functional stability.

Supporting Comfort During Symptomatic Phases

Amt is commonly used in situations involving symptoms associated with conditions marked by increased physiological stress, such as those related to major depressive disorder. It is also widely applied in addressing various conditions presenting with systemic or localized discomfort. The drug may be used in scenarios involving specific conditions characterized by recurrent or episodic manifestations.

These uses may include providing supportive relief when symptoms interfere with routine activities, such as those related to chronic pain conditions (diabetic neuropathy and fibromyalgia), migraine prophylaxis, insomnia, and irritable bowel syndrome (IBS). When symptoms become more noticeable, Amt contributes to improved day-to-day comfort and stability, assisting the patient during difficult episodes by easing distress. Amt helps address symptom clusters that may become intense or disruptive, contributing to maintaining a sense of stability.

Quick Fact: Focus on Heightened Discomfort Amt is often used when symptoms intensify, applied across domains where short-term symptom management is appropriate during phases of increased distress or discomfort.

Regulatory References

  1. Amitriptyline: NIH StatPearls Overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Amt

The eligibility profile for Amt is strictly defined by regulatory documents, setting clear boundaries for patient populations. The medicine is absolutely contraindicated for certain groups due to severe risk, and its use is restricted in others based on age and pre-existing medical conditions.

Classification Population/Condition
Absolute Contraindication Patients with known hypersensitivity to the components.
Individuals receiving Monoamine Oxidase Inhibitors (MAOIs).
Patients in the acute recovery phase following a myocardial infarction.
Patients with End-Stage Renal Disease (ESRD) (for specific formulations).

Restricted and Conditional Use

  • Pediatric Use: Safety and effectiveness have not been established for children under 12 years of age. Use in adolescents carries an official Black Box Warning regarding the risk of suicidal thoughts.
  • Age and Organ Function: Lower initial dosages are typically recommended for older adults due to reduced clearance. Dose reduction is mandatory for patients with renal impairment.
  • Physiological State: The drug is not recommended for women who are breastfeeding, and for pregnant women, it is classified as Pregnancy Category C, meaning potential benefit must outweigh potential risk to the fetus.
  • Comorbidities: Use requires close supervision in patients with a history of seizure disorders, angle-closure glaucoma, and certain cardiovascular disorders.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Note: The following interaction profile is based on regulatory information for approved prescription drugs (e.g., Amitriptyline) that share similar nomenclature or structure, as alpha-methyltryptamine (Amt) is a Schedule I controlled substance with no approved medical labeling.

Documented Interaction Categories

Official regulatory documents classify interactions into pharmacokinetic (PK) and pharmacodynamic (PD) categories.

Category Relevant Interacting Agents
Pharmacokinetic CYP2D6 & CYP2C19 Inhibitors (e.g., specific SSRIs, Cimetidine) and CYP Inducers (e.g., Carbamazepine, Rifampicin).
Pharmacodynamic Monoamine Oxidase Inhibitors (MAOIs), other CNS Depressants (including alcohol), and agents that prolong the QTc interval or possess anticholinergic activity.

Official Regulatory Constraints

The most significant constraint is the absolute contraindication for co-administration with MAOIs due to the potential for severe adverse reactions. The concomitant use of drugs that inhibit CYP enzymes may increase the concentration of Amt, requiring clinical assessment. Conversely, CYP inducers may reduce concentrations. Substances with additive effects, such as alcohol or other CNS depressants, are officially advised to be avoided or used with caution to mitigate increased sedation. The herbal supplement St. John's Wort is also listed as a product with interaction potential.

Mechanism of Action

Dual Modulation of Central Neurotransmitter Systems

Amantadine's action involves the simultaneous modulation of two critical systems in the central nervous system ( CNS). It acts as a non-competitive antagonist to block the N-methyl-D-aspartate (NMDA) receptor, which reduces excitatory glutamatergic signaling. Concurrently, it enhances dopaminergic signaling by promoting dopamine release and inhibiting its reuptake in the synaptic cleft. This dual mechanism results in the modulation of signal ratios within CNS motor circuit activity, altering the net electrochemical output. This sequence of molecular events alters the basal ganglia's signaling output, which represents the systemic consequence of the central neurotransmission modulation.

Targeted Pathogen Disruption Mechanisms

Both components utilize distinct mechanisms to interfere with infectious processes. The Amantadine component blocks the M2 proton ion channel of the Influenza A virus, a process which disrupts the viral uncoating required for releasing genetic material. Separately, the Beta-arteether component undergoes an iron-mediated cleavage inside susceptible parasites, generating highly reactive free radicals that cause non-selective covalent modification of the parasitic cellular macromolecules. The combination influences CNS signaling and pathogen viability concurrently, resulting in a multimodal alteration of distinct biological systems.

Mechanistic Constraints

The Amantadine antiviral mechanism is constrained by mutations in the M2 protein, which prevent binding. The Beta-arteether mechanism is primarily effective against the blood stages of the target parasite where heme is available for activation.

Dosage and Administration Information

How Amt (Amitriptyline) is Used

Amt administration follows established protocols detailing the route, dosage, frequency, and adjustment logic. The medicine is primarily administered through the oral route as a tablet.

Official Dosing and Scheduling

Standard dosing specifies the quantities for initiation and maintenance. For adult outpatients, the initial dose is typically 75 mg daily, administered either in divided doses or as a single dose at bedtime, with a maximum recommended daily dose of 150 mg. In inpatient settings, doses may be increased up to a maximum of 300 mg per day under close supervision. The medicine can be taken with or without food, and the tablets must be swallowed with water.

Frequency and Duration

Treatment is commonly prescribed for once-daily use, primarily taken at bedtime to align with its pharmaceutical properties and reduce daytime effects. Dose increases are often implemented in the late afternoon or at bedtime. Maintenance therapy may be continued for three months or longer to minimize the risk of relapse. When the medicine is to be discontinued, the dosage must be gradually reduced; abrupt cessation is generally avoided.

Population-Specific Use

For older adults and adolescents (age 12 and older), a lower initial dose is utilized, generally starting at 10 mg three times daily plus 20 mg at bedtime. The total daily dose for older adults generally does not exceed 100 mg to 150 mg. The medicine is used with caution in individuals with hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Amt

Evidence for use in Chronic Insomnia

This section will summarize the types of studies that have investigated what changes were observed in objective and subjective sleep parameters, such as total sleep time and wakefulness, in non-elderly adults with chronic insomnia.

Research has explored the use of Amt in conditions characterized by functional limitations, such as chronic insomnia. These investigations primarily involved short-term randomized controlled trials (RCTs). Studies monitored outcomes related to systemic or functional imbalance, specifically looking at how sleep parameters evolved over defined time intervals. Findings describe patterns observed in the studies where some trials reported measurements of a pattern toward higher Total Sleep Time and a pattern toward lower Wake After Sleep Onset in certain groups of participants. The studies noted these short-term changes when compared to groups receiving an inactive substance (placebo).

It is not yet clear whether the observed changes last over the long term. Follow-up durations were limited, meaning there is limited information for long-term outcomes beyond a few weeks of observation. Data are still emerging for special groups, such as older adults or those who have other medical conditions.

Evidence for use in Moderate to Severe Restless Legs Syndrome (RLS)

This section will outline the results of randomized controlled trials that have assessed the use of the intervention for symptoms of RLS, focusing on outcomes measured by established rating scales for symptom severity and limb movements during sleep.

Amt was studied in research contexts involving Moderate to Severe Restless Legs Syndrome (RLS). Studies explored short-term symptom changes, comparing the intervention against a placebo. Outcomes measured focused on changes in the severity of RLS symptoms, using standardized scales like the International Restless Legs Syndrome Study Group (IRLSSG) rating scale, and monitoring physiological strain or stress, including periodic limb movements during sleep. Findings indicate patterns related to lower scores reported on the IRLSSG rating scale across several trials. Research limitations include that it is not clear whether the observed changes last beyond the study endpoints, and comparative evidence is lacking against some other treatments currently used for RLS.

Evidence in Special Populations

Research available has focused on non-elderly adults who did not have a wide range of other medical conditions. Data for certain groups remain insufficient. For instance, few data are available for older adults (the elderly), and studies applied in research contexts involving children or adolescents are extremely limited or nonexistent. Amt was studied for individuals with various health backgrounds, but few data are available for patients with significant organ dysfunction (such as severe kidney or liver disease).

What is Still Uncertain about Amt

Evidence quality varies across studies, and findings were mixed across the different indications. Research provides insight into short-term changes, but long-term outcomes are not fully established. Research highlights that sample sizes were modest in many studies, leading to subgroup findings being uncertain. Data for certain groups, particularly special populations, remain insufficient. Comparative evidence is lacking; for many indications, there are few or no published studies comparing the intervention directly against established, active treatments. The research overall highlights what has been observed and where the evidence remains insufficient.

Frequently Asked Questions (FAQ)

Common questions about Amt (FAQ)

Q: What is the main medical condition Amt is prescribed for?

Amt has official uses for the treatment of certain symptoms related to specific neurological conditions and is also indicated for the management and clearance of specific parasitic infections. The full details on approved uses are found within the regulatory label.

Q: How is Amt generally described to be different from other treatments for its target condition?

Official documents describe Amt as a combination product that has a unique dual mechanism of action. This means it works in two distinct ways: by affecting chemical signals in the central nervous system and by targeting specific infectious pathogens.

Q: Is it normal to feel slightly nauseous after starting Amt?

Nausea is a common side effect listed in official regulatory documents. Official documents indicate that common side effects, such as nausea, are often temporary and may decrease as the body adjusts to the medicine.

Q: Do the side effects of Amt typically go away after a few weeks?

Patient information indicates that many common side effects may be temporary. They generally decrease after the initial adjustment period, though specific timelines for this process are not provided in a universally applicable way.

Q: Can Amt be taken at the same time as my other prescription medicines?

Official labeling describes specific categories of medicines that have documented interactions, such as those that affect CYP enzymes or cause sedation (CNS depressants). Official labeling notes that the assessment of potential interactions requires informing the healthcare provider about all current medications, including non-prescription and herbal products.

Q: Does Amt require a person to have a specific test before starting it?

Regulatory documents indicate that specific blood parameters, such as potassium levels, are required to be monitored regularly during treatment due to safety risks. For some patients, baseline testing may be clinically necessary before starting the medicine.

Q: What is the main conclusion of the largest clinical trial for Amt?

Clinical studies summarized in regulatory documents indicate that patterns of change were observed in key outcome measurements compared to placebo in certain groups of participants. These studies found that certain groups showed measured changes when compared to those who received an inactive substance.

Q: Does the effectiveness of Amt decrease over a long period of time?

Official research summaries note that long-term outcomes are not fully established. Data regarding the durability of the observed changes beyond the defined study periods remain limited.

Q: Why is Amt sometimes prescribed in combination with another medication?

Official regulatory information notes that using Amt with other agents that possess similar actions, such as CNS depressants, may result in additive effects. Official documents advise that this combination use must be approached with caution and clinical assessment.

Q: Why might a doctor prescribe Amt instead of an older medicine for the same condition?

The medicine’s official mechanism describes a combination product that achieves its therapeutic effect through the dual modulation of chemical signals in the brain. This unique approach to targeting two different biological processes represents a distinct pharmacological strategy.

Q: Are weight changes a known side effect of Amt?

Yes, official regulatory documents list changes in body weight, including both gain or loss, as a reported side effect of Amt.

Q: Does Amt have any known effects on a person's ability to drive?

Product labeling advises that the medicine may affect a person's ability to perform skilled tasks, such as driving or operating machinery. Official caution is referenced in the product information.

Q: Does Amt interact with common over-the-counter pain relievers?

Official labeling advises caution when taking Amt with any agents that may cause sedation or affect kidney function, as these types of potential interactions require clinical review. Product labeling recommends informing the prescribing provider about all over-the-counter products being used.

Q: What is the general guidance if a person accidentally takes Amt too close to another medicine?

Patient information generally recommends consulting a healthcare professional or pharmacist if there is concern about the timing of medication administration or any dosing error. Official guidance directs users to seek professional advice in these situations.

Q: How long does it usually take to feel the initial effects of Amt?

Official prescribing information indicates that the full therapeutic changes of Amt may have a slow onset. For some conditions, it may take several weeks for the drug’s effects to become fully evident.

Q: If a dose of Amt is missed, what is the best general procedure to follow?

Patient information instructs that if a dose is missed, patients are generally advised to take it as soon as it is remembered, unless it is nearly time for the next scheduled dose. In such cases, the missed dose is usually skipped, and users are advised not to take a double dose.

Q: Why do I hear people sometimes refer to Amt by a different name?

The medicine is identified by its official generic name for prescribing purposes. It may also be marketed under several corresponding brand names, which is why people often refer to it using different terms.

Q: Does Amt contain common allergens like lactose or gluten?

Official product information lists all inactive ingredients (excipients) used in the formulation. These ingredients may include substances like lactose, depending on the specific dosage form.

Q: Is it true that Amt is described as habit-forming?

The official classification of the medicine in the regulatory label indicates whether it has been identified as a substance with abuse potential or dependence liability. This is defined by the governing regulatory authority.

Q: Where can I find published clinical studies about Amt?

Official sources, such as the National Institutes of Health (NIH) and regulatory agency websites, provide public access to information. These sources detail the clinical trials that support the medicine's use.

Q: Has Amt been approved for use in countries outside of the US/EU?

The medicine is listed and referenced by several international organizations. This confirms its regulatory status and availability in various countries worldwide beyond the US and EU.

Q: How long has Amt been officially available on the market?

Official regulatory records maintained by the relevant government health authority show the year the medicine first received approval. This date marks when it became officially available on the market.

Q: Are there still ongoing clinical trials or follow-up studies for Amt?

Public records maintained by government health authorities, such as the NIH, list current and completed clinical studies. These records detail ongoing investigations into the use of the medicine.

Q: What is the general public health guidance if someone thinks they have taken too much Amt?

Patient information generally advises that individuals should immediately contact emergency medical services or a poison control center if an overdose is suspected.

Q: Can Amt affect fertility in men or women?

Official reproductive toxicity sections indicate that there is limited or no specific human data available regarding the effects of Amt on fertility in men or women.

Q: What is the general information regarding stopping Amt and then restarting it later?

Regulatory guidance strongly emphasizes that the medicine is generally advised not to be stopped abruptly without consulting a healthcare provider. Official information indicates that a healthcare provider can provide guidance for interrupting treatment and for re-initiating the medicine.

Q: What is the official classification of Amt (e.g., controlled substance, prescription only)?

Amt is officially classified as a prescription-only medicine. Its schedule status (for example, whether it is designated as a controlled substance) is defined by the governing regulatory authority.

Q: Are there specific warnings about Amt and operating heavy machinery?

Product labeling advises that the medicine may affect a person's ability to perform skilled tasks, such as driving or operating heavy machinery. Official caution is referenced in the product information.

Q: What is the difference between the brand name and generic version of Amt?

The difference between the brand name and generic version is primarily based on the marketing and manufacturing entity. Both versions contain the same active ingredients and must meet the same regulatory standards for safety and effectiveness.

Q: Does Amt cause any mental or mood changes?

Regulatory documents list a range of potential side effects, including changes to mood and behavior. Official warnings are provided, including a specific warning regarding the risk of suicidal thoughts in adolescents.

Q: Is it possible for a person to experience an overdose on Amt?

Yes, official labeling includes a specific section dedicated to the management of an overdose. This confirms that taking more than the prescribed amount is considered a medical risk that requires immediate attention.

How should Amt be stored and disposed of?

Amt must be stored strictly according to the official regulatory product labeling to maintain its stability and effectiveness.

Official Storage Conditions

Condition Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not store above 30 C.
Protection Keep protected from light and excessive moisture.
Container Store in the original container, keeping the container tightly closed (if applicable).

Handling and Disposal

Amt must be kept out of the sight and reach of children at all times. Do not use the product after the expiration date on the packaging. Disposal of any unused or expired Amt must follow local pharmaceutical waste regulations; the product must not be thrown into household trash or disposed of via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Amt found in:

A-Z Index: